Mahchid BAMDAD

Prof. Mahchid BAMDAD

orcid

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 September 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
AGAbderrahim El Guerrab
Abderrahim El Guerrab
MBMahchid BAMDAD
Mahchid BAMDAD
FKFabrice Kwiatkowski
Fabrice Kwiatkowski
YBYves-Jean Bignon
Yves-Jean Bignon
FPFrédérique Penault-Llorca
Frédérique Penault-Llorca
CACorinne Aubel
Corinne Aubel
Oncotarget | https://doi.org/10.18632/oncotarget.12037 Abderrahim El Guerrab, Mahchid Bamdad, Fabrice Kwiatkowski, Yves-Jean Bignon, Frédérique Penault-Llorca, Corinne Aubel Anti-EGFR monoclonal antibodies and EGFR tyrosine kinase inhibitors as combination therapy for triple-negative breast cancer

22 September 2000 in Glia
Verified
Journal Article
Closed access
PDF file
SGStéphane Gobron
Stéphane Gobron
ICIsabelle Creveaux
Isabelle Creveaux
RMRobert Meiniel
Robert Meiniel
RDRobert Didier
Robert Didier
AHAlain Herbet
Alain Herbet
AMAnnie Meiniel
Annie Meiniel

14 April 2020 in Scientific Reports
Verified
Journal Article
Open access
PDF file
AGAbderrahim El Guerrab
Abderrahim El Guerrab
MBMahchid BAMDAD
Mahchid BAMDAD
YBYves-Jean Bignon
Yves-Jean Bignon
FPFrédérique Penault-Llorca
Frédérique Penault-Llorca
CACorinne Aubel
Corinne Aubel
Triple-negative breast cancers (TNBC) are unlikely to respond to hormonal therapies and anti-HER2-targeted therapies. TNBCs overexpress EGFR and exhibit constitutive activation of the PI3K/AKT/mTOR signalling pathway. We hypothesized that simultaneously blocking EGFR and mTOR could be a potential therapeutic strategy for the treatment of TNBC. We examined the antitumour activity of the mTOR inhibitor everolimus combined with the EGFR tyrosine kinase inhibitor gefitinib in TNBC cell with or without activating mutations in the PI3K/AKT/mTOR signalling pathway. We demonstrated that everolimus and gefitinib induced synergistic growth inhibition in the PI3K and PTEN-mutant CAL-51 cell line but not in the PTEN-null HCC-1937 cell line. The antiproliferative effect was associated with synergistic inhibition of mTOR and P70S6K phosphorylation, as well as a significant reduction in 4E-BP1 activation in the CAL-51 cell line. We also showed that combination therapy significantly inhibited cell cycle progression and increased apoptosis in this cell line. Gene and protein expression analysis revealed significant downregulation of cell cycle regulators after exposure to combined treatment. Collectively, these results suggested that dual inhibition of mTOR and EGFR may be an effective treatment for TNBC with activating mutations of PI3K.

24 August 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
CDClémence Dubois
Clémence Dubois
RDRobin Dufour
Robin Dufour
PDPierre DAUMAR
Pierre DAUMAR
CACorinne Aubel
Corinne Aubel
CSClaire Szczepaniak
Claire Szczepaniak
MBMahchid BAMDAD
Mahchid BAMDAD
Development and cytotoxic response of two proliferative MDA-MB-231 and non-proliferative SUM1315 three-dimensional cell culture models of triple-negative basal-like breast cancer cell lines Development and cytotoxic response of two proliferative MDA-MB-231 and non-proliferative SUM1315 three-dimensional cell culture models of triple-negative basal-like breast cancer cell lines

3 August 2015 in Scientific Reports
Verified
Journal Article
Open access
RDRobin Dufour
Robin Dufour
PDPierre DAUMAR
Pierre DAUMAR
EMEmmanuelle Mounetou
Emmanuelle Mounetou
CACorinne Aubel
Corinne Aubel
FKFabrice Kwiatkowski
Fabrice Kwiatkowski
MBMahchid BAMDAD
Mahchid BAMDAD
The triple negative basal-like (TNBL) breast carcinoma is an aggressive and unfavorable prognosis disease. Inhibitors of poly(ADP-ribose) polymerase such as Olaparib could represent a promising targeted therapy but their sensitivity against Multidrug Resistance proteins (MDR), which causes resistance, is not well defined. Thus, our work focused on the analysis of P-gp and BCRP coexpression in the SUM1315 TNBL human cell line, in correlation with Olaparib intracellular concentration. Western blot analyses showed a clear coexpression of P-gp and BCRP in SUM1315 cells. A low cytotoxic Olaparib treatment clearly led to an increased expression of both BCRP and P-gp in these cells. Indeed, after 1.5 h of treatment, BCRP expression was increased with a 1.8 fold increase rate. Then, P-gp took over from 3 h to 15 h with an average increase rate of 1.8 fold and finally returned to control value at 24 h. HPLC-UV analyses showed that, in the same treatment conditions, the intracellular Olaparib concentration increased from 1 h to 3 h and remained relatively stable until 24 h. Results suggest that the resistance mechanism induced by Olaparib in TNBL SUM1315 cell line may be overpassed if a cytotoxic and stable intracellular level of the drug can be maintained.

1 July 2007 in Environmental Toxicology and Chemistry
Verified
Journal Article
Closed access
PDF file
CVChristel Vache
Christel Vache
OCOlivier Camares
Olivier Camares
MCMarie- Céleste
Marie- Céleste
CFCardoso- Ferreira
Cardoso- Ferreira
BDBernard Dastugue
Bernard Dastugue
MBMahchid BAMDAD
Mahchid BAMDAD
Polycyclic aromatic hydrocarbons (PAHs) are a major source of air, water, and soil pollution. The multidrug resistance (mdr)/permeability glycoprotein (P-gp) complex is implicated in the multidrug resistance pattern developed against various drugs and xenobiotics, including polycyclic aromatic hydrocarbons. In order to develop a genomic biomarker, we investigated the response of the mdr49 gene (mdr49) of Drosophila melanogaster to PAHs. Structural analysis of mdr49-PA, which is the putative protein expressed from Drosophila mdr49gene, demonstrated that this transmembrane protein indeed belongs to the adenosine triphosphate-binding cassette transporter superfamily. Polymerase chain reaction (PCR) and real-time PCR analysis revealed that the mdr49 gene is expressed continuously at all the stages of fly development, including embryos, pupae, larvae, and adults, as well as in embryonic Drosophila S12 cells. In the adult fly, the mdr49 gene was expressed in all the analyzed segments (head, thorax, and abdomen) and organs (olfactory and sexual organs). The quantification of mdr49 transcripts by real-time PCR in adult flies exposed to benzo[a]pyrene over time or in presence of increasing concentrations of this pollutant showed a clear dose-dependent response. Similarly, mdr49 gene expression increased after adult flies were exposed to structurally varied PAHs. The detection of tested PAHs by Drosophila P-gp efflux pump was checked by flow cytometry.